ReviewImmunologic research2026
Research on chronic urticaria and angioedema: A bibliometric analysis of Web of Science Core Collection.
Review in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Chronic urticaria is a common mast-cell-driven inflammatory disorder characterized by recurrent wheals, angioedema, or both. Angioedema is associated with higher disease burden, impaired quality of life, and greater difficulty in clinical assessment, yet the overall research structure of chronic urticaria in the context of angioedema has not been systematically mapped. Publications were retrieved from the Web of Science Core Collection on July 14, 2026. English-language Articles and Reviews published between 1947 and 2026 were included after independent screening by two researchers, with disagreements resolved by a third researcher. Bibliometrix, VOSviewer, CiteSpace, Scimago Graphica, and GraphPad Prism were used to analyze annual output, countries, institutions, authors, journals, co-cited references, and keyword evolution. A total of 881 publications were included. Annual output increased over time, with faster growth after 2014. The United States ranked first in productivity, Germany had the highest citation count and total link strength, and Charité - Universitätsmedizin Berlin was the leading institution. The knowledge base was concentrated in mast cell biology, autoimmune mechanisms, anti-IgE therapy, and patient-reported outcomes. Keyword analysis showed a shift from early immune plausibility and idiopathic descriptions toward disease standardization, quality of life, and targeted therapy, including omalizumab and newer targeted treatments. Angioedema remained a high-frequency term and was repeatedly linked to disease burden, assessment, and treatment. The literature addressing both chronic urticaria and angioedema showed increasing emphasis on structured clinical assessment, mast-cell and autoimmune mechanisms, patient-reported outcomes, biomarker-oriented stratification, and targeted treatment. Future research should broaden international participation and evaluate clinically useful biomarkers and patient-centered outcomes across diverse populations.
Indexed as
Identifiers
42566088What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.